FDA expands use of Novartis MS drug to pediatric patients
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG's relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Children | Food and Drug Administration (FDA) | Gilenya | Health | Multiple Sclerosis | Pediatrics